ECSP13012650A - Métodos y composiciones para tratar diarrea asociada con vih - Google Patents

Métodos y composiciones para tratar diarrea asociada con vih

Info

Publication number: ECSP13012650A
Authority: EC; Ecuador
Prior art keywords: diarrhea; methods; hiv; compositions; diarrhea associated
Prior art date: 2010-10-31

Application number

Other languages

English (en)

Spanish (es)

Inventor

William Forbes

Enoch Bortey

Steven King

Pravin Chaturvedi

Original Assignee

Salix Pharmaceuticals Ltd

Napo Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-31

Filing date

2013-05-31

Publication date

2013-10-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45994461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012650(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-31 Application filed by Salix Pharmaceuticals Ltd, Napo Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Ltd

2013-10-31 Publication of ECSP13012650A publication Critical patent/ECSP13012650A/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)

ECSP13012650 2010-10-31 2013-05-31 Métodos y composiciones para tratar diarrea asociada con vih ECSP13012650A (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US40862210P	2010-10-31	2010-10-31
US40933510P	2010-11-02	2010-11-02
US41624910P	2010-11-22	2010-11-22
US201161434379P	2011-01-19	2011-01-19

Publications (1)

Publication Number	Publication Date
ECSP13012650A true ECSP13012650A (es)	2013-10-31

Family

ID=45994461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ECSP13012650 ECSP13012650A (es)	2010-10-31	2013-05-31	Métodos y composiciones para tratar diarrea asociada con vih

Country Status (20)

Country	Link
US (4)	US8962680B2 (fr)
EP (1)	EP2632550B1 (fr)
JP (2)	JP6063385B2 (fr)
CN (2)	CN107595836A (fr)
AU (1)	AU2011320155B2 (fr)
BR (1)	BR112013010774A2 (fr)
CA (1)	CA2816416C (fr)
DK (1)	DK2632550T3 (fr)
EC (1)	ECSP13012650A (fr)
ES (1)	ES2635435T3 (fr)
HK (1)	HK1249036A1 (fr)
HU (1)	HUE035393T2 (fr)
MX (1)	MX348184B (fr)
PE (1)	PE20140036A1 (fr)
PH (1)	PH12013500857A1 (fr)
PL (1)	PL2632550T3 (fr)
PT (1)	PT2632550T (fr)
RU (1)	RU2597746C2 (fr)
WO (1)	WO2012058664A1 (fr)
ZA (1)	ZA201303136B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070254050A1 (en)	2006-05-01	2007-11-01	Quart Barry D	Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2007130892A2 (fr)	2006-05-01	2007-11-15	Napo Pharmaceuticals, Inc.	Méthode de traitement du syndrome du côlon irritable à constipation prédominante
EP2529626B1 (fr) *	2006-05-01	2017-11-22	Napo Pharmaceuticals, Inc.	Compositions et méthodes pour le traitement ou la prévention du cancer du côlon
PL2632550T3 (pl)	2010-10-31	2017-10-31	Napo Pharmaceuticals Inc	Sposoby i kompozycja do leczenia biegunki związanej z HIV
MX2015007065A (es) *	2012-12-07	2017-03-01	Napo Pharmaceuticals Inc	Metodo y composiciones para tratar diarrea asociada con vih.
US11389424B2 (en)	2017-03-09	2022-07-19	Napo Pharmaceuticals, Inc.	Methods and compositions for treating chemotherapy-induced diarrhea
IL270984B2 (en)	2017-05-31	2026-05-01	Napo Pharmaceuticals Inc	Methods and preparations for treating congenital diarrheal disorder
WO2018222921A1 (fr)	2017-05-31	2018-12-06	Napo Pharmaceuticals, Inc.	Procédés et compositions pour le traitement de la diarrhée causée par les acides biliaires, de la diarrhée associée à une résection de l'intestin grêle ou à l'ablation de la vésicule biliaire, et du syndrome de l'intestin court
EP3935581A4 (fr)	2019-03-04	2022-11-30	Iocurrents, Inc.	Compression et communication de données à l'aide d'un apprentissage automatique
IL299028A (en) *	2020-06-19	2023-02-01	Napo Pharmaceuticals Inc	Methods and compositions for treating chemotherapy-induced diarrhea
WO2022115481A1 (fr) *	2020-11-24	2022-06-02	Napo Pharmaceuticals, Inc.	Procédés et compositions pour le traitement de troubles gastro-intestinaux d'une infection post-aiguë

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5211944A (en)	1990-10-12	1993-05-18	Shaman Pharmaceuticals, Inc.	Proanthocyanidin polymers having antiviral activity and methods of obtaining same
EP0935417B1 (fr)	1996-10-16	2009-05-06	Napo Pharmaceuticals, Inc.	Formulations enterales de compositions polymeres pro-anthocyanidiques a proprietes anti-diarrheiques
WO2000047062A2 (fr) *	1999-02-01	2000-08-17	Shaman Pharmaceuticals, Inc.	Formulations entero-solubles de supplements a base de polymeres de proanthocyanidine et procedes associes
US20040071793A1 (en)	2002-10-05	2004-04-15	Bobrowski Paul J.	Oral rehydration methods and compositions
US20080025966A1 (en) *	2004-01-30	2008-01-31	Currie Mark G	Methods And Compositions For The Treatment Of Gastrointestinal disorders
CA2667449A1 (fr) *	2005-06-22	2007-01-04	University Of Massachusetts	Inhibiteurs de la protease du vih-1, et leurs procedes de fabrication et d'utilisation
WO2007068383A1 (fr)	2005-12-15	2007-06-21	Bayer Healthcare Ag	Urees de diaryle pour le traitement d'infections virales
EP2529626B1 (fr)	2006-05-01	2017-11-22	Napo Pharmaceuticals, Inc.	Compositions et méthodes pour le traitement ou la prévention du cancer du côlon
WO2007130892A2 (fr) *	2006-05-01	2007-11-15	Napo Pharmaceuticals, Inc.	Méthode de traitement du syndrome du côlon irritable à constipation prédominante
US20070254050A1 (en)	2006-05-01	2007-11-01	Quart Barry D	Method for treatment of diarrhea-predominant irritable bowel syndrome
WO2010021681A2 (fr)	2008-08-18	2010-02-25	Combinatorx (Singapore) Pte. Ltd.	Compositions et procédés pour le traitement de maladies virales
US7928115B2 (en)	2008-10-02	2011-04-19	Salix Pharmaceuticals, Ltd.	Methods of treating travelers diarrhea and hepatic encephalopathy
WO2011024049A2 (fr)	2009-08-26	2011-03-03	Glenmark Pharmaceuticals Ltd	Procédé pour produire des compositions polymères proanthocyanidines pour des préparations pharmaceutiques
JP2013506716A (ja) *	2009-10-06	2013-02-28	ザレゲンツオブジユニヴァーシティオブカリフォルニア	クロフェレマーなどのプロアントシアニジンオリゴマーを用いて疾患を治療する方法
US20110087530A1 (en)	2009-10-09	2011-04-14	Visa U.S.A. Inc.	Systems and Methods to Provide Loyalty Programs
PL2632550T3 (pl)	2010-10-31	2017-10-31	Napo Pharmaceuticals Inc	Sposoby i kompozycja do leczenia biegunki związanej z HIV
BR112013018688B1 (pt)	2011-01-27	2021-08-24	Napo Pharmaceuticals, Inc	Método de produção de uma composição polimérica de proantocianidina
MY197454A (en)	2011-12-22	2023-06-19	Napo Pharmaceuticals Inc	Non-enteric pharmaceutical composition comprising crofelemer
MX2015007065A (es)	2012-12-07	2017-03-01	Napo Pharmaceuticals Inc	Metodo y composiciones para tratar diarrea asociada con vih.

2011
- 2011-10-31 PL PL11837249T patent/PL2632550T3/pl unknown
- 2011-10-31 CN CN201711077144.7A patent/CN107595836A/zh active Pending
- 2011-10-31 MX MX2013004873A patent/MX348184B/es active IP Right Grant
- 2011-10-31 CA CA2816416A patent/CA2816416C/fr active Active
- 2011-10-31 BR BR112013010774A patent/BR112013010774A2/pt not_active Application Discontinuation
- 2011-10-31 AU AU2011320155A patent/AU2011320155B2/en active Active
- 2011-10-31 PE PE2013000926A patent/PE20140036A1/es not_active Application Discontinuation
- 2011-10-31 WO PCT/US2011/058549 patent/WO2012058664A1/fr not_active Ceased
- 2011-10-31 ES ES11837249.9T patent/ES2635435T3/es active Active
- 2011-10-31 EP EP11837249.9A patent/EP2632550B1/fr active Active
- 2011-10-31 PH PH1/2013/500857A patent/PH12013500857A1/en unknown
- 2011-10-31 PT PT118372499T patent/PT2632550T/pt unknown
- 2011-10-31 JP JP2013536904A patent/JP6063385B2/ja active Active
- 2011-10-31 HU HUE11837249A patent/HUE035393T2/en unknown
- 2011-10-31 RU RU2013123794/15A patent/RU2597746C2/ru active
- 2011-10-31 CN CN2011800637391A patent/CN103370101A/zh active Pending
- 2011-10-31 DK DK11837249.9T patent/DK2632550T3/en active
- 2011-10-31 US US13/285,397 patent/US8962680B2/en active Active
- 2011-11-11 US US13/294,307 patent/US20120107370A1/en not_active Abandoned
2013
- 2013-04-29 ZA ZA2013/03136A patent/ZA201303136B/en unknown
- 2013-05-31 EC ECSP13012650 patent/ECSP13012650A/es unknown
2014
- 2014-06-17 US US14/307,175 patent/US20140294903A1/en not_active Abandoned
2015
- 2015-01-15 US US14/597,740 patent/US9585868B2/en active Active
2016
- 2016-08-02 JP JP2016151656A patent/JP6310971B2/ja active Active
2018
- 2018-07-09 HK HK18108819.2A patent/HK1249036A1/zh unknown

Also Published As

Publication number	Publication date
HUE035393T2 (en)	2018-05-02
EP2632550A1 (fr)	2013-09-04
PL2632550T3 (pl)	2017-10-31
JP2013540826A (ja)	2013-11-07
US20120107370A1 (en)	2012-05-03
JP6063385B2 (ja)	2017-01-18
DK2632550T3 (en)	2017-08-07
WO2012058664A1 (fr)	2012-05-03
BR112013010774A2 (pt)	2017-03-21
US8962680B2 (en)	2015-02-24
CN103370101A (zh)	2013-10-23
HK1249036A1 (zh)	2018-10-26
PT2632550T (pt)	2017-08-02
PE20140036A1 (es)	2014-01-31
JP6310971B2 (ja)	2018-04-11
AU2011320155A1 (en)	2013-05-09
US20120184605A1 (en)	2012-07-19
PH12013500857A1 (en)	2018-01-17
EP2632550B1 (fr)	2017-05-03
US20140294903A1 (en)	2014-10-02
MX348184B (es)	2017-06-02
US9585868B2 (en)	2017-03-07
EP2632550A4 (fr)	2014-04-23
CA2816416C (fr)	2020-02-11
RU2597746C2 (ru)	2016-09-20
US20150190367A1 (en)	2015-07-09
ES2635435T3 (es)	2017-10-03
MX2013004873A (es)	2013-08-21
CN107595836A (zh)	2018-01-19
RU2013123794A (ru)	2014-12-10
CA2816416A1 (fr)	2012-05-03
JP2017019806A (ja)	2017-01-26
ZA201303136B (en)	2016-01-27
AU2011320155B2 (en)	2016-02-25

Publication	Publication Date	Title
MX2013004873A (es)	2013-08-21	Metodos y composiciones para tratar diarrea asociada con vih.
MX382400B (es)	2025-03-13	Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea.
NZ602219A (en)	2014-10-31	Methods and compositions for treating degos’ disease
ECSP12012106A (es)	2013-05-31	Terapia antiviral
CR20140410A (es)	2014-11-17	Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
EA201201186A1 (ru)	2013-11-29	ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
CR11724A (es)	2011-06-07	Agente para tratar enfermedades
AR093247A1 (es)	2015-05-27	Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
CO6821938A2 (es)	2013-12-31	Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
MX2015013184A (es)	2016-04-07	Composiciones de peliculas sublingual y bucal.
MX2021005172A (es)	2021-07-15	Compuestos de union a nhe3 (intercambiador de sodio-hidrogeno 3) y metodos para inhibir el transporte de fosfato.
BR112012013487A2 (pt)	2017-10-03	Composições de amantadina e métodos de uso
MX2020004516A (es)	2020-10-20	Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas.
MX2011011596A (es)	2012-02-01	Perifosina y capecitabina como un tratamiento combinado para cancer.
BR112014019350A8 (pt)	2017-07-11	Composição terapêutica estéril, seu uso para tratar diarreia induzida por rotavírus e embalagem
ECSP13012551A (es)	2013-06-28	Terapia de combinación para tratar infección por hcv.
DOP2013000131A (es)	2013-11-15	Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
MX2020007462A (es)	2020-09-14	Metodos de tratamiento de enfermedades inflamatorias cronicas.
MX2015007065A (es)	2017-03-01	Metodo y composiciones para tratar diarrea asociada con vih.
TR200900879A2 (tr)	2010-08-23	Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
CO6731081A2 (es)	2013-08-15	Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
CO6670518A2 (es)	2013-05-15	Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos
MX2014003873A (es)	2014-05-28	Metodo para tratar el carcinoma mucoepidermoide.
MY180772A (en)	2020-12-09	Novel therapeutic mirtazapine combinations for use in pain disorders
CO6771411A2 (es)	2013-10-15	Metodos y composiciones para tratar diarrea asociada al vih